2.92 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||2.84 x 1100|
|Ask||3.50 x 800|
|Day's Range||2.7800 - 2.9200|
|52 Week Range||2.3900 - 9.7500|
|Beta (3Y Monthly)||2.21|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.33|
The big shareholder groups in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have Read More...
CORAL GABLES, FL / ACCESSWIRE / December 21, 2018 / The pharmaceutical industry is predicated on the notion that treatments for various ailments can always be improved upon, and patients suffering from these diseases both demand and need better treatment options. As pharmaceutical companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety may benefit from these efforts. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals, Inc (SGYP), Pieris Pharmaceuticals, Inc (PIRS), and Obalon Therapeutics Inc (OBLN) are 4 pharma stocks representing companies invested in creating the best quality drug treatments for their patients.
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
Steve Yoder has been the CEO of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
P.A.W. Capital Partners is a Greenwich-based hedge fund launched at the end of 1990 by its current Chief Investment Officer, General Partner and Senior Portfolio Manager, Peter A. Wright. After leading his fund for 28 years, and considering his previous work history, Peter Wright has more than 30 years of experience in the securities industry. […]
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 26.67% and 35.54%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boston-based company said it had a loss of 11 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a ...
Company to Host an Investor Conference Call on Wednesday, November 7, 2018 at 8:00 AM EST BOSTON, Nov. 07, 2018 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a.
BOSTON, Oct. 31, 2018 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology.
Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Matthew L. Sherman, M.D., has joined the Company’s Board of Directors. Dr. Sherman is a physician-scientist with clinical development expertise in oncology, hematology and pulmonary diseases across large pharma, biopharma and venture-funded biotechnology startup companies. Most recently, Dr. Sherman was Executive Vice President and Chief Medical Officer at Acceleron Pharma.
Pieris Pharmaceuticals Inc (NASDAQ:PIRS), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PIRS Read More...
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -100.00% and -13.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Boston-based company said it had a loss of less than 1 cent. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 1 cent per share. ...